Searched for
LUPIN Q3
These large- and mid-cap stocks can give more than 25% return in 1 year, according to analystsThere are market phases when one risk dominates. Then there are phases like this, when risks arrive from every direction and refuse to stan...- Mankind, other pharma stocks rally up to 7%; Nifty Pharma scales fresh peak. What lies ahead?Pharma stocks surged on Wednesday, supported by strong earnings and a weakening rupee, even as Sensex and Nifty traded lower. The Nifty Pha...
- Small & midcaps rally! Wockhardt, Coforge, other stocks surge up to 14%. Do you own any?Smallcap and midcap stocks surged on Wednesday, outperforming broader market indices with gains of around 1% each. This rally was fueled by...
- GST department initiates inspection and search ops at Lupin's officeMaharashtra's Goods & Services Tax Department has initiated inspection and search proceedings at Lupin's registered office. The pharmaceuti...
- Lupin Q3 Results: Net profit triples to Rs 619 crore on sales growthThe company reported a net profit of Rs 158 crore in the corresponding quarter of the previous year. Revenue from operations grew 20.2% YoY...
- Lupin Q3 Results: Net profit declines 72% YoY to Rs 153.5 croreThe earnings before interest, tax, depreciation and amortisation (EBITDA) increased 44% YoY to Rs 532.7 crore for the quarter, with EBITDA ...
- Lupin Q3 Results: Net profit up 24% at Rs 545 crThe Mumbai-based drugmaker had reported a net profit of Rs 438.3 crore in the October-December quarter of the previous fiscal.
- Lupin Q3 results: Net profit at Rs 438.25 croreThe company had posted a net loss of Rs 835 crore for the corresponding period of the previous fiscal, Lupin said in a late night filing to...
- Lupin Q2 results: Net profit at Rs 211 crore"We are very pleased with the strong recovery of our business during the quarter, demonstrated by sequential growth across all our geograph...
- Lupin Q3 results: Loss widens to Rs 835 crore on higher taxTax expenses for the quarter jumped to Rs 767 crore from Rs 245.40 crore.
- Lupin falls nearly 4% after poor Q3 showCredit Suisse has maintained 'Underperform' view on the stock with a target price at Rs 800 per share.
- Key takeaways from Lupin’s Q3 earningsUS sales jumped 13.50 per cent QoQ to Rs 1417.40 crore in Q3FY19.
- Lupin reports Rs 152 crore Q3 loss on one-time hit from European suit; sales rise 12% to Rs 4,378 croreAnalysts in an ET Now poll had projected a profit of Rs 268 crore.
- Lupin Q3 results today: Here's what experts sayAccording to an ET Now poll, the drug maker is likely to report a 7 per cent YoY jump in net sales.
- Lupin Q3 net drops 64% YoY to Rs 309 croreTotal revenue from operations stood at Rs 2,531.25 against Rs 3,295.52 crore last year.
- Credit Suisse sees Lupin’s EPS hit as Fortamet, Glumetza losing volume sharePrescriptions for Fortamet and Glumetza market are down 13% QoQ (quarter on quarter), which could impact FY18 EPS for Lupin by 5%.
- Lupin Q3 net profit rises 26% to Rs 601 croreNet sales of the company rose to Rs 3,144.91 crore for quarter under review as compared to Rs 2,982.97 crore in the same period of previous...
- Lupin Q3 jumps nearly 41 per cent to Rs 483.74 croreNet sales of Lupin in Q3, 2013-14 rose to Rs 2,982.97 crore as against Rs 2,465.87 crore in the same period of previous fiscal.
- Lupin's net up by 33.4 pc in Q1 FY13Lupin's consolidated net profit by 33.4 per cent to Rs 280.4 crore in the quarter ended June 30, 2012 as against Rs 210.1 crore during the ...
- Lupin Q3 net up 4.95 per cent at Rs 235.1 croreDrug firm Lupin said its consolidated net profit rose by 4.95%to Rs 235.1 crore for the third quarter ended December 31, 2011, over the sam...
Load More
